Respuesta :
Answer: C. Cancer
Explanation:
Current cancer immunotherapies mainly focus on CD8+ T cells. Given the heterogeneous nature of cancer, personalized cancer immunotherapy that integrates the power of both CD8+ T cells in adaptive immunity and NK cells in innate immunity might be the future direction, along with precision targeting and effective delivery of tumor-specific, memory CD8+ T cells and NK cells.